Buprenorphine and a CRF1 Antagonist Block the Acquisition of Opiate Withdrawal-Induced Conditioned Place Aversion in Rats
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Conditioned place aversion in rats has face validity as a measure of the aversive stimulus effects of opiate withdrawal that reflects an important motivational component of opiate dependence. The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of opiate withdrawal. Male Sprague-Dawley rats were implanted with two subcutaneous morphine pellets and 5 days later began place conditioning training following subcutaneous administration of a low dose of naloxone. Animals were subjected to three pairings of a low dose of naloxone (15 microg/kg, s.c.) to one arm of a three-chambered place conditioning apparatus. Buprenorphine administered prior to each pairing dose-dependently blocked the place aversion produced by precipitated opiate withdrawal. A corticotropin-releasing factor-1 (CRF1) receptor antagonist (antalarmin) also reversed the place aversion produced by precipitated opiate withdrawal. Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats. No effect was observed with pretreatment of the dopamine partial agonist terguride or the selective serotonin reuptake inhibitor fluoxetine. Also, chronic pretreatment with acamprosate (a glutamate receptor modulator used to prevent relapse in alcohol depend…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of a CRF receptor antagonist has been found to decrease opioid withdrawal-induced negative emotional states (54) and attenuated heroin self-administration in animals with extended access to the drug (55).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [54]
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Self-citationDrug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535 · cited 1×
“The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of…”
BackgroundSelf-citationKoob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Buprenorphine’s partial agonist properties limit its abuse liability (Jasinski et al, 1978), and it recently has been approved for use in the treatment opiate dependence (Johnson and McCagh, 2000; Tzschentke, 2002; Substance Abuse and Mental Health Services Administration, 2002).”
BackgroundZobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705 · cited 1×
“…that blocked shockinduced freezing did not compromise HPA axis responses to stress (Deak et al, 1999), and in clinical study the CRF1 antagonist R121919 produced anxiolytic-like effects in depressed patients in the absence of effects on basal or CRF-stimulated HPA axis measures (Zobel et al, 2000).”
BackgroundDynamics of Drug Dependence: Implications of a Conditioning Theory for Research and Treatment
Wikler, A. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750350005001 · Cited by 648 · cited 2×
“Opiate addiction long has been thought to involve multiple sources of reinforcement (Wikler, 1973).”
BackgroundCorticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · cited 2×
“Because norepinephrine may release CRF in the basal forebrain, and CRF activates norepinephrine function in the pons, there is the possibility of a feedforward system involved in the aversive stimulus effects of opiate withdrawal as well as stress in general (Koob, 1999; Valentino et al, 1993).”
BackgroundSelf-citationPich, E., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G., & Weiss, F. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05439.1995 · Cited by 565 · cited 2×
“Studies using in vivo microdialysis have shown that rats withdrawn from chronic alcohol, withdrawn from chronic cocaine, and precipitously withdrawn from chronic cannabinoids show increases in the release of CRF from the central nucleus of the amygdala (Cummings et al, 1983; Merlo-Pich et al, 1995; Rodriguez de Fonsec…”
BackgroundSelf-citationA role for corticotropin releasing factor and urocortin in behavioral responses to stressors
Koob, G. F., & Heinrichs, S. C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01991-5 · Cited by 531 · cited 1×
“These same central CRF systems are well documented to contribute to behavioral responses to stressors (Koob et al, 1994; Koob and Heinrichs, 1999).”
BackgroundSelf-citationAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528 · cited 1×
“Buprenorphine is an opioid partial agonist at the m opioid receptor and a k opioid antagonist (Cowan et al, 1977).”
BackgroundActivation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499 · cited 2×
“…from opiates and other drugs of dependence, including cocaine, alcohol, opiates, and tetrahydrocannabinol, and thus may mediate some of the motivational effects associated with acute abstinence (Heinrichs et al, 1995; Koob et al, 1994; Richter and Weiss, 1999; Rodriguez de Fonseca et al, 1997).”
BackgroundSelf-citationNoradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion
Delfs, J. M., Zhu, Y., Druhan, J. P., & Aston-Jones, G. (2000) · Nature · doi:10.1038/35000212 · Cited by 462 · cited 2×
“Particularly intriguing are recent studies demonstrating a role for norepinephrine in the bed nucleus of the stria terminalis in the conditioned place aversions associated with opiate withdrawal (Delfs et al, 2000).”
BackgroundCummings, S., Elde, R., Ells, J., & Lindall, A. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-07-01355.1983 · Cited by 414 · cited 1×
“…have shown that rats withdrawn from chronic alcohol, withdrawn from chronic cocaine, and precipitously withdrawn from chronic cannabinoids show increases in the release of CRF from the central nucleus of the amygdala (Cummings et al, 1983; Merlo-Pich et al, 1995; Rodriguez de Fonseca et al, 1997).”
BackgroundRassnick, S., Heinrichs, S. C., Britton, K. T., & Koob, G. F. (1993) · Brain Research · doi:10.1016/0006-8993(93)91352-s · Cited by 407 · cited 2×
“For example, animals exposed to chronic cocaine and alcohol show significant anxiety-like responses following cessation of chronic drug administration, which are reversed with intracerebroventricular administration of a CRF antagonist (Rassnick et al, 1993; Sarnyai et al, 1995).”
BackgroundSelf-citationRECENT PROGRESS IN RESEARCH ON THE NEUROPHYSIOLOGIC BASIS OF MORPHINE ADDICTION
WIKLER, A. (1948) · American Journal of Psychiatry · doi:10.1176/ajp.105.5.329 · Cited by 392 · cited 1×
“Opiate withdrawal is associated with aversive effects that have motivational significance (Wikler, 1948, 1973; Wikler and Pescor, 1967).”
BackgroundAllostasis, amygdala, and anticipatory angst
Schulkin, J., McEwen, B. S., & Gold, P. W. (1994) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)90051-5 · Cited by 380 · cited 1×
“In addition, high circulating levels of glucocorticoids can feedback to shut off the HPA axis and can ‘sensitize’ the CRF systems in the central nucleus of the amygdala known to be involved in behavioral responses to stressors (Lee et al, 1994; Schulkin et al, 1994; Shepard et al, 2000).”
BackgroundShepard, J. D., Barron, K. W., & Myers, D. A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02019-9 · Cited by 321 · cited 1×
“In addition, high circulating levels of glucocorticoids can feedback to shut off the HPA axis and can ‘sensitize’ the CRF systems in the central nucleus of the amygdala known to be involved in behavioral responses to stressors (Lee et al, 1994; Schulkin et al, 1994; Shepard et al, 2000).”
BackgroundStinus, L., Le Moal, M., & Koob, G. F. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90106-e · Cited by 317 · cited 4×
“These results suggest that buprenorphine blocks the aversive stimulus effects of precipitated opiate withdrawal in rats and provides some validity for the use of place conditioning as a measure that is sensitive to potential opiate-dependence medications.”
BackgroundSelf-citationShaham, Y., Funk, D., Erb, S., Brown, T. J., Walker, C.-D., & Stewart, J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02605.1997 · Cited by 308 · cited 2×
“CRF also has been implicated in the reinstatement of heroin- and cocaine-seeking behavior associated with stressor exposure in rats (Shaham et al, 1997, 1998).”
BackgroundShaham, Y., Erb, S., Leung, S., Buczek, Y., & Stewart, J. (1998) · Psychopharmacology · doi:10.1007/s002130050608 · Cited by 302 · cited 2×
“CRF also has been implicated in the reinstatement of heroin- and cocaine-seeking behavior associated with stressor exposure in rats (Shaham et al, 1997, 1998).”
BackgroundAnti-craving compounds for ethanol: new pharmacological tools to study addictive processes
Spanagel, R., & Zieglgänsberger, W. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)89800-8 · Cited by 291 · cited 3×
“Potential antiexpression effects of acamprosate were explored because of its glutamatemodulating neuropharmacological effects and its use as an antirelapse medication (Spanagel and Zieglgansberger, 1997).”
BackgroundInfluentialSchulteis, G., Markou, A., Gold, L. H., Stinus, L., & Koob, G. F. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24024-1 · Cited by 285 · cited 2×
“The doses of naloxone required to precipitate a place aversion are below those that produce overt physical or somatic signs of opiate withdrawal (Schulteis et al, 1994).”
BackgroundSelf-citationAcute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283 · cited 1×
“Buprenorphine also produced an inverted dose–response function for respiratory depression (Walsh et al, 1995) and gastrointestinal transit (Cowan, 1992).”
BackgroundAcamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat
Spanagel, R., Hölter, S. M., Allingham, K., Landgraf, R., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00174-4 · Cited by 274 · cited 1×
“On days 6, 8, and 10 postpellet implantation, rats received 15 mg/kg s.c. of naloxone immediately prior to confinement in the naloxone-paired compartment for 20 min.”
MethodWikler, A., & Pescor, F. T. (1967) · Psychopharmacologia · doi:10.1007/bf00401386 · Cited by 269 · cited 1×
“Opiate withdrawal is associated with aversive effects that have motivational significance (Wikler, 1948, 1973; Wikler and Pescor, 1967).”
BackgroundSarnyai, Z., Bíró, É., Gardi, J., Vecsernyés, M., Julesz, J., & Telegdy, G. (1995) · Brain Research · doi:10.1016/0006-8993(95)00043-p · Cited by 255 · cited 1×
“For example, animals exposed to chronic cocaine and alcohol show significant anxiety-like responses following cessation of chronic drug administration, which are reversed with intracerebroventricular administration of a CRF antagonist (Rassnick et al, 1993; Sarnyai et al, 1995).”
BackgroundDeak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., Licinio, J., Wong, M.-L., Chrousos, G. P., Webster, E., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6415 · Cited by 242
Heinrichs, S. C., Menzaghi, F., Schulteis, G., Koob, G. F., & Stinus, L. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199501000-00011 · Cited by 226 · cited 3×
“…from opiates and other drugs of dependence, including cocaine, alcohol, opiates, and tetrahydrocannabinol, and thus may mediate some of the motivational effects associated with acute abstinence (Heinrichs et al, 1995; Koob et al, 1994; Richter and Weiss, 1999; Rodriguez de Fonseca et al, 1997).”
BackgroundSelf-citationRichter, R. M., & Weiss, F. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990615)32:4%3c254::aid-syn2%3e3.0.co;2-h · Cited by 207 · cited 2×
“…from opiates and other drugs of dependence, including cocaine, alcohol, opiates, and tetrahydrocannabinol, and thus may mediate some of the motivational effects associated with acute abstinence (Heinrichs et al, 1995; Koob et al, 1994; Richter and Weiss, 1999; Rodriguez de Fonseca et al, 1997).”
BackgroundBoismare, F., Daoust, M., Moore, N., Saligaut, C., Lhuintre, J. P., Chretien, P., & Durlach, J. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(84)80020-9 · Cited by 184 · cited 1×
“…been shown in animal models to block the excessive drinking associated with deprivation, dependence, and individual differences (Gewiss et al, 1991; Boismare et al, 1984; Le Magnen et al, 1987; Spanagel et al, 1996a; Holter et al, 1997; Heyser et al, 1998), and in humans has been shown in several…”
BackgroundFrenois, F., Cador, M., Caillé, S., Stinus, L., & Le Moine, C. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02187.x · Cited by 179 · cited 2×
“These results suggest that buprenorphine blocks the aversive stimulus effects of precipitated opiate withdrawal in rats and provides some validity for the use of place conditioning as a measure that is sensitive to potential opiate-dependence medications.”
BackgroundSelf-citationHeyser, C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00130-9 · Cited by 176 · cited 1×
“…dependence, and individual differences (Gewiss et al, 1991; Boismare et al, 1984; Le Magnen et al, 1987; Spanagel et al, 1996a; Holter et al, 1997; Heyser et al, 1998), and in humans has been shown in several multicenter clinical trials to increase abstinence and prevent relapse in detoxified…”
Zeise, M. L., Kasparov, S., Capogna, M., & Zieglgänsberger, W. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90682-8 · Cited by 175 · cited 1×
“…have suggested that acamprosate may be acting as a partial co-agonist at the N-methyl-D-aspartate receptor (Spanagel and Zieglgansberger, 1997; Zeise et al, 1993; Dahchour et al, 1998; Koob et al, 2002; al Qatari et al, 1998; Naassila et al, 1998), a neuropharmacological action that might…”
BackgroundDahchour, A., De Witte, P., Bolo, N., Nédélec, J.-F., Muzet, M., Durbin, P., & Macher, J.-P. (1998) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(98)00016-x · Cited by 165 · cited 1×
“…that acamprosate may be acting as a partial co-agonist at the N-methyl-D-aspartate receptor (Spanagel and Zieglgansberger, 1997; Zeise et al, 1993; Dahchour et al, 1998; Koob et al, 2002; al Qatari et al, 1998; Naassila et al, 1998), a neuropharmacological action that might explain its blockade…”
BackgroundNaassila, M., Hammoumi, S., Legrand, E., Durbin, P., & Daoust, M. (1998) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199806000-00005 · Cited by 164 · cited 1×
“…N-methyl-D-aspartate receptor (Spanagel and Zieglgansberger, 1997; Zeise et al, 1993; Dahchour et al, 1998; Koob et al, 2002; al Qatari et al, 1998; Naassila et al, 1998), a neuropharmacological action that might explain its blockade of excessive drinking and attenuation of the motivational…”
BackgroundZorrilla, E. P., Valdez, G. R., Nozulak, J., Koob, G. F., & Markou, A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03189-x · Cited by 159 · cited 1×
“Antalarmin hydrochloride, a nonpeptide noncompetitive CRF1 receptor antagonist, was suspended in acidified carboxymethylcellullose (0.5%), dissolved in saline (pH of diluent was 5.5), sonicated, and injected i.p. in a volume of 4 ml/kg as described previously (Zorrilla et al, 2002).”
MethodSelf-citationCorticotropin releasing factor, stress and behavior
Koob, G. F., Heinrichs, S. C., Menzaghi, F., Pich, E. M., & Britton, K. T. (1994) · Seminars in Neuroscience · doi:10.1006/smns.1994.1029 · Cited by 141 · cited 2×
“These same central CRF systems are well documented to contribute to behavioral responses to stressors (Koob et al, 1994; Koob and Heinrichs, 1999).”
BackgroundSelf-citationGold, L. H., Stinus, L., Inturrisi, C. E., & Koob, G. F. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90755-2 · Cited by 136 · cited 1×
“As previously shown, full dependence to morphine, as measured by naloxone-precipitated opiate withdrawal, is achieved 24 h following morphine pellet implantation and remains constant for at least 12 days (Gold et al, 1994).”
BackgroundSelf-citationGracy, K. N., Dankiewicz, L. A., & Koob, G. F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00186-x · Cited by 135 · cited 1×
“The development of conditioned aversions to precipitated opiate withdrawal appears to depend on elements of the basal forebrain (Stinus et al, 1990; Frenois et al, 2002; Gracy et al, 2001), and more specifically a connection through the basolateral amygdala (Schulteis et al, 2000).”
BackgroundKoob, G. F., Pettit, H. O., Ettenberg, A., & Bloom, F. E. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21967-x · Cited by 120 · cited 2×
“…Cedex, France; 2Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA Conditioned place aversion in rats has face validity as a measure of the aversive stimulus effects of opiate withdrawal that reflects an important motivational component of opiate dependence.”
BackgroundSelf-citationHand, T. H., Koob, G. F., Stinus, L., & Moal, M. L. (1988) · Brain Research · doi:10.1016/0006-8993(88)90452-0 · Cited by 119 · cited 6×
“Because norepinephrine may release CRF in the basal forebrain, and CRF activates norepinephrine function in the pons, there is the possibility of a feedforward system involved in the aversive stimulus effects of opiate withdrawal as well as stress in general (Koob, 1999; Valentino et al, 1993).”
BackgroundSelf-citationTreatment of alcohol-dependent outpatients with acamprosate: a clinical review.
Mason, B. J. (2001) · PubMed · Cited by 117
Porrino, L. J., Ritz, M. C., Goodman, N. L., Sharpe, L. G., Kuhar, M. J., & Goldberg, S. R. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90418-9 · Cited by 117 · cited 3×
“Fluoxetine, at a dose shown to block reuptake in rats (Wong et al, 1985) and decrease cocaine self-administration (Porrino et al, 1989), failed to block conditioned place aversion to opiate withdrawal.”
BackgroundMethodLee, Y., Schulkin, J. A., & Davis, M. (1994) · Brain Research · doi:10.1016/0006-8993(94)90286-0 · Cited by 114 · cited 1×
“In addition, high circulating levels of glucocorticoids can feedback to shut off the HPA axis and can ‘sensitize’ the CRF systems in the central nucleus of the amygdala known to be involved in behavioral responses to stressors (Lee et al, 1994; Schulkin et al, 1994; Shepard et al, 2000).”
Backgroundal Qatari, M., Bouchenafa, O., & Littleton, J. (1998) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199806000-00006 · Cited by 114 · cited 1×
“…co-agonist at the N-methyl-D-aspartate receptor (Spanagel and Zieglgansberger, 1997; Zeise et al, 1993; Dahchour et al, 1998; Koob et al, 2002; al Qatari et al, 1998; Naassila et al, 1998), a neuropharmacological action that might explain its blockade of excessive drinking and attenuation of…”
BackgroundOpiate withdrawal-induced place aversion lasts for up to 16 weeks
Stinus, L., Caillé, S., & Koob, G. F. (2000) · Psychopharmacology · doi:10.1007/s002139900358 · Cited by 101 · cited 3×
“The place aversion response does not require maintenance Online publication: 16 April 2004 at http://www.acnp.org/citations/ Npp04160403540/default.pdf Received 24 November 2003; revised 05 April 2004; accepted 14 April 2004 *Correspondence: Dr L Stinus, Laboratoire de Neuropsychobiologie des Desadaptations, Universit…”
BackgroundSelf-citationAcamprosate and alcohol: II. Effects on alcohol withdrawal in the rat
Spanagel, R., Putzke, J., Stefferl, A., Schöbitz, B., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00175-6 · Cited by 100
GEWISS, M., HEIDBREDER, C., OPSOMER, L., DURBIN, P., & DE WITTE, P. (1991) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045093 · Cited by 98 · cited 1×
“Acamprosate has been shown in animal models to block the excessive drinking associated with deprivation, dependence, and individual differences (Gewiss et al, 1991; Boismare et al, 1984; Le Magnen et al, 1987; Spanagel et al, 1996a; Holter et al, 1997; Heyser et al, 1998), and in humans has been…”
BackgroundLe Magnen, J., Tran, G., Durlach, J., & Martin, C. (1987) · Alcohol · doi:10.1016/0741-8329(87)90005-x · Cited by 97 · cited 1×
“…to block the excessive drinking associated with deprivation, dependence, and individual differences (Gewiss et al, 1991; Boismare et al, 1984; Le Magnen et al, 1987; Spanagel et al, 1996a; Holter et al, 1997; Heyser et al, 1998), and in humans has been shown in several multicenter clinical…”
BackgroundLu, L., Liu, D., Ceng, X., & Ma, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.01310.x · Cited by 89 · cited 1×
“…effects were observed using the conditioned place preference model where both a nonspecific CRF antagonist and a selective CRF1 antagonist, but not a CRF2 antagonist, blocked the stress- and morphine-induced reinstatement of place preference following a 28-day extinction (Lu et al, 2000a, b).”
Wong, D. T., Reid, L. R., Bymaster, F. P., & Threlkeld, P. G. (1985) · Journal of Neural Transmission · doi:10.1007/bf01256471 · Cited by 88 · cited 1×
“Fluoxetine, at a dose shown to block reuptake in rats (Wong et al, 1985) and decrease cocaine self-administration (Porrino et al, 1989), failed to block conditioned place aversion to opiate withdrawal.”
BackgroundTime Course of Acamprosate Action on Operant Ethanol Self‐Administration after Ethanol Deprivation
Hölter, S. M., Landgraf, R., Zieglgänsberger, W., & Spanagel, R. (1997) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1997.tb03850.x · Cited by 87 · cited 1×
“…with deprivation, dependence, and individual differences (Gewiss et al, 1991; Boismare et al, 1984; Le Magnen et al, 1987; Spanagel et al, 1996a; Holter et al, 1997; Heyser et al, 1998), and in humans has been shown in several multicenter clinical trials to increase abstinence and prevent…”
Lu, L., Ceng, X., & Huang, M. (2000) · NeuroReport · doi:10.1097/00001756-200008030-00008 · Cited by 81 · cited 1×
“…effects were observed using the conditioned place preference model where both a nonspecific CRF antagonist and a selective CRF1 antagonist, but not a CRF2 antagonist, blocked the stress- and morphine-induced reinstatement of place preference following a 28-day extinction (Lu et al, 2000a, b).”
Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction
Tzschentke, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1003-8 · Cited by 81 · cited 1×
“Buprenorphine’s partial agonist properties limit its abuse liability (Jasinski et al, 1978), and it recently has been approved for use in the treatment opiate dependence (Johnson and McCagh, 2000; Tzschentke, 2002; Substance Abuse and Mental Health Services Administration, 2002).”
BackgroundConditioning and opiate withdrawal
Schulteis, G., Ahmed, S. H., Morse, A. C., Koob, G. F., & Everitt, B. J. (2000) · Nature · doi:10.1038/35016630 · Cited by 77 · cited 1×
“The development of conditioned aversions to precipitated opiate withdrawal appears to depend on elements of the basal forebrain (Stinus et al, 1990; Frenois et al, 2002; Gracy et al, 2001), and more specifically a connection through the basolateral amygdala (Schulteis et al, 2000).”
BackgroundSelf-citationCorticotropin-releasing factor induces a place aversion independent of its neuroendocrine role
Cador, M., Ahmed, S. H., Koob, G. F., Le Moal, M., & Stinus, L. (1992) · Brain Research · doi:10.1016/0006-8993(92)91487-y · Cited by 74 · cited 1×
“When injected intracerebroventricularly, CRF is aversive and produces place aversions (Cador et al, 1992) and taste aversions (Heinrichs et al, 1991) and raises brain stimulation reward thresholds (Macey et al, 2000).”
BackgroundSelf-citationDopamine‐dependent responses to cocaine depend on corticotropin‐releasing factor receptor subtypes
Lu, L., Liu, Z., Huang, M., & Zhang, Z. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01635.x · Cited by 71 · cited 1×
“Antalarmin had no effect of its own in producing place conditioning, an observation consistent with the lack of a place preference with CP-154,526, a structurally similar CRF1 antagonist (Lu et al, 2003).”
ResultMacey, D. J., Koob, G. F., & Markou, A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02229-0 · Cited by 69 · cited 1×
“When injected intracerebroventricularly, CRF is aversive and produces place aversions (Cador et al, 1992) and taste aversions (Heinrichs et al, 1991) and raises brain stimulation reward thresholds (Macey et al, 2000).”
BackgroundSelf-citationDopamine Partial Agonist Reverses Amphetamine Withdrawal in Rats
Orsini, C., Koob, G. F., & Pulvirenti, L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00270-6 · Cited by 67 · cited 1×
“…terguride at a dose that blocks cocaine selfadministration (Pulvirenti et al, 1998), methamphetamine self-administration (O Kitamura, GF Koob, L Pulvirenti, unpublished results), and psychostimulant withdrawal (Orsini et al, 2001) failed to block conditioned place aversion to opiate withdrawal.”
BackgroundCole, J. C., Littleton, J. M., & Little, H. J. (2000) · Psychopharmacology · doi:10.1007/s002130050009 · Cited by 65 · cited 2×
“Acamprosate also has some effects in preventing aversive effects associated with ethanol withdrawal (Spanagel et al, 1996b; Cole et al, 2000).”
BackgroundBuprenorphine and Naloxone for Heroin Dependence
Johnson, R. E., & McCagh, J. C. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0012-8 · Cited by 65 · cited 1×
“Buprenorphine’s partial agonist properties limit its abuse liability (Jasinski et al, 1978), and it recently has been approved for use in the treatment opiate dependence (Johnson and McCagh, 2000; Tzschentke, 2002; Substance Abuse and Mental Health Services Administration, 2002).”
BackgroundPotential Neuroprotective Effects of Acamprosate
Koob, G. F., Mason, B. J., De Witte, P., Littleton, J., & Siggins, G. R. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1097/00000374-200204000-00021 · Cited by 57 · cited 1×
“…be acting as a partial co-agonist at the N-methyl-D-aspartate receptor (Spanagel and Zieglgansberger, 1997; Zeise et al, 1993; Dahchour et al, 1998; Koob et al, 2002; al Qatari et al, 1998; Naassila et al, 1998), a neuropharmacological action that might explain its blockade of excessive drinking…”
BackgroundSelf-citationRapid Induction of Conditioned Opiate Withdrawal in the Rat
Baldwin, H. A., & Koob, G. F. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.3 · Cited by 55 · cited 2×
“…because its manifestation continues to be present weeks after animals are ‘detoxified’ (eg up to 16 weeks after the morphine pellets are removed; see Baldwin and Koob, 1993; Hand et al, 1988; Stinus et al, 1990, 2000), which clearly indicates that the memory of withdrawal can have…”
BackgroundSelf-citationBuprenorphine: Bell-shaped dose-response curve for its antagonist effects
Lizasoaín, I., Leza, J. C., & Lorenzo, P. L. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90452-c · Cited by 54 · cited 1×
“Buprenorphine produces antinociception in animal models with a potency at least 25 that of morphine (Cowan, et al, 1977), but the dose–effect function is a Ushaped curve (Lizasoain et al, 1991).”
BackgroundSpanagel, R., Sillaber, I., Zieglgänsberger, W., Corrigall, W. A., Stewart, J., & Shaham, Y. (1998) · Psychopharmacology · doi:10.1007/s002130050730 · Cited by 51 · cited 2×
“Indeed, one study showed that acamprosate attenuated the locomotor sensitization associated with repeated opiate administration (Spanagel et al, 1998).”
BackgroundResultPulvirenti, L., Balducci, C., Piercy, M., & Koob, G. F. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37716-x · Cited by 51 · cited 3×
“Also, the treatment interval varied between drugs based on their pharmacokinetic differences (see Spanagel et al, 1996a, b, 1998; Porrino et al, 1989; Cole et al, 2000; Pulvirenti et al, 1998).”
BackgroundMethodSelf-citationBuprenorphine self-administration by rhesus monkey
Mello, N. K., Bree, M. P., & Mendelson, J. H. (1981) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(81)90180-5 · Cited by 49 · cited 1×
“Buprenorphine is selfadministered by primates but has less efficacy than full agonists and produces less withdrawal (Mello et al, 1981; Lukas et al, 1983).”
BackgroundBoth conditioned taste preference and aversion induced by corticotropin-releasing factor
Heinrichs, S. C., Britton, K. T., & Koob, G. F. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90075-d · Cited by 46 · cited 1×
“When injected intracerebroventricularly, CRF is aversive and produces place aversions (Cador et al, 1992) and taste aversions (Heinrichs et al, 1991) and raises brain stimulation reward thresholds (Macey et al, 2000).”
BackgroundSelf-citationCowan, A. (1992) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1992.tb00396.x · Cited by 16 · cited 1×
“Buprenorphine also produced an inverted dose–response function for respiratory depression (Walsh et al, 1995) and gastrointestinal transit (Cowan, 1992).”
BackgroundKINETIC STUDY OF ACAMPROSATE ABSORPTION IN RAT SMALL INTESTINE
Más‐Serrano, P. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.4.324 · Cited by 15 · cited 1×
“Chronic administration was used because acamprosate has poor absorption and must be given chronically to attain meaningful brain levels (Mas-Serrano et al, 2000).”
Buprenorphine self-administration by the baboon: comparison with other opioids.
Lukas, S. E., Griffiths, R. R., & Jv, B. (1983) · PubMed · Cited by 14
Preclinical Behavioral Models for Addressing Unmet Needs in Opiate Addiction
Schulteis, G., Gold, L. H., & Koob, G. F. (1997) · Seminars in Neuroscience · doi:10.1006/smns.1997.0110 · Cited by 10 · cited 2×
“Male Sprague–Dawley rats were implanted with two subcutaneous morphine pellets and 5 days later began place conditioning training following subcutaneous administration of a low dose of naloxone.”
BackgroundMethodSelf-citationPascucci, T., Cioli, I., Pisetzky, F., Duprè, S., Spirito, A., & Nencini, P. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0524 · Cited by 6 · cited 1×
“These results actually are consistent with studies showing that acamprosate does not generalize to morphine in drug discrimination studies and does not block the reinforcing effects of heroin (Pascucci et al, 1999; Spanagel et al, 1998).”
Result
Research works printed but not linked: 1
- Valentino RJ, Foote SL, Page ME (1993). The locus coeruleus as a site for integrating corticotropin-eleasing factor and noradrenergic mediation of stress responses. In: Tache Y, Rivier C (eds). Corticotropin-Releasing Factor and Cytokines: Role in the Stress Response (series title: Annals of the New York Academy of Sciences, Vol. 697). New York Academy of Sciences: New York. pp 173–188.
Cited by
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
“Systemic administration of a CRF1 receptor antagonist and direct intracerebral administration of a peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-induced place aversions (Stinus et al, 2005; Heinrichs et al, 1995).”
BackgroundSelf-citationTzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056
“A CRF1/CRF2 peptide antagonist injected into the central nucleus of the amygdala and systemic administration of CRF1 antagonists blocked conditioned place aversion associated with precipitated opiate withdrawal (Heinrichs et al., 1995; Stinus et al., 2005).”
Self-citationAddiction as a stress surfeit disorder
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L., Whitfield, T. W., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.024 · Cited by 483
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript by naloxone in morphine-dependent rats (Stinus et al., 2005), and a CRF peptide antagonist injected into the CeA also reversed the place aversion produced by methylnaloxonium injected into the CeA (Heinrichs et al.,…”
BackgroundMethodSelf-citationRole of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Self-citation
Metadata
- Authors
- Stinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F.
- Affiliations
- Université de Bordeaux (FR)
- Scripps Research Institute (US)
- Corresponding author
- Stinus, Luis
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-12
- Volume
- 30
- Issue
- 1
- Pages
- 90-98
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1980693070
- Cited by
- 139
- References
- 73
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 8 · 2013: 6 · 2012: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Université de Bordeaux
- National Institutes of Health
- National Institute on Drug Abuse (DA04043, R01DA004043)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- buprenorphine, corticotropin-releasing factor 1 receptor, antalarmin, opioid withdrawal, conditioned place aversion, morphine dependence, naloxone, place conditioning, acamprosate, terguride, fluoxetine, glutamate receptor modulation
- MeSH terms
- Acamprosate, CRF Receptor, Type 1, Analgesics, Opioid, Animals, Avoidance Learning, Buprenorphine, Conditioning, Operant, Dose-Response Relationship, Drug, Drug Implants, Fluoxetine, Lisuride, Male, Morphine, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Pyrimidines, Pyrroles, Substance Withdrawal Syndrome, Taurine, Rats, Sprague-Dawley, Receptors, Corticotropin-Releasing Hormone, Antidepressive Agents, Second-Generation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.